Since 2011, three different anti-VEGF drugs, bevacizumab, ranibizumab, and aflibercept, have been tested in clinical trials to investigate their efficiency, bioavailability, and functional outcomes for ROP patients [17,18,19,20]. This evidence concerns the gene VEGFA and retinopathy of prematurity.